Akili IncNASDAQ:AKLINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2380
- TODAY'S CHANGE (%)0.0058 (2.4978%)
- Bid / Lots0.2339/ 5
- Ask / Lots0.2380/ 5
- Open / Previous Close0.2375 / 0.2322
- Day Range
- 52 Week Range
- Volume51,257
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AKLI |
|---|---|---|
| 09:32 ET | 6815 | 0.2493 |
| 09:36 ET | 1200 | 0.24 |
| 09:50 ET | 2100 | 0.233 |
| 09:57 ET | 3861 | 0.2399 |
| 10:17 ET | 400 | 0.2398 |
| 10:28 ET | 500 | 0.234 |
| 10:37 ET | 757 | 0.2364 |
| 10:44 ET | 1000 | 0.23883 |
| 10:50 ET | 10779 | 0.247099 |
| 10:51 ET | 1114 | 0.2471 |
| 11:00 ET | 400 | 0.2529 |
| 11:02 ET | 2523 | 0.2341 |
| 11:18 ET | 320 | 0.2435 |
| 11:24 ET | 2000 | 0.2435 |
| 11:47 ET | 100 | 0.24 |
| 11:56 ET | 2000 | 0.243 |
| 12:05 ET | 200 | 0.243 |
| 12:27 ET | 400 | 0.2451 |
| 12:38 ET | 100 | 0.240101 |
| 12:50 ET | 1000 | 0.2498 |
| 12:52 ET | 450 | 0.24 |
| 12:54 ET | 100 | 0.2498 |
| 01:26 ET | 156 | 0.2449 |
| 01:37 ET | 5000 | 0.2401 |
| 01:42 ET | 273 | 0.2395 |
| 02:31 ET | 100 | 0.24 |
| 02:45 ET | 100 | 0.234 |
| 03:00 ET | 400 | 0.2408 |
| 03:14 ET | 200 | 0.24 |
| 03:38 ET | 200 | 0.2406 |
| 03:56 ET | 1480 | 0.238 |
| 03:59 ET | 340 | 0.238 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Akili Inc | 18.7M | -0.3x | --- |
PAVmed Inc | 17.1M | -0.2x | --- |
QT Imaging Holdings Inc | 17.8M | -2.1x | --- |
Positron Corp | 28.7M | -12.8x | --- |
BioSig Technologies Inc | 15.8M | -0.3x | --- |
ALR Technologies Inc | 14.8M | -1.8x | --- |
Company Information
Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company’s approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.
Contact Information
- Headquarters
- 71 Commercial Street, Mailbox 312BOSTON, MA, United States 02109
- Phone
- 617-456-0597
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Co-Founder
- W. Martucci
- President, Chief Executive Officer, Director
- Matthew Franklin
- Co-Founder, Director
- Adam Gazzaley
- Chief Legal Officer, Secretary
- Jacqueline Studer
- Independent Director
- Mary Hentges
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.7M |
|---|---|
Revenue (TTM) | $1.7M |
Shares Outstanding | 78.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.76 |
Book Value | $0.75 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 11.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,842.97% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
